milciclib   Click here for help

GtoPdb Ligand ID: 7938

Synonyms: PHA 848125 | PHA-848125 | PHA848125
PDB Ligand
Compound class: Synthetic organic
Comment: Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and neurotrophic tyrosine kinase, receptor, type 1 (aka TRKA) [1]. It is compound 28 in Brasca et al (2009) [1]. Milciclib exhibits a notable level of promiscuity across the CDKs [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 91.21
Molecular weight 460.27
XLogP 2.48
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CNC(=O)c1nn(c2c1C(C)(C)Cc1c2nc(nc1)Nc1ccc(cc1)N1CCN(CC1)C)C
Isomeric SMILES CNC(=O)c1nn(c2c1C(C)(C)Cc1c2nc(nc1)Nc1ccc(cc1)N1CCN(CC1)C)C
InChI InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29)
No information available.
Summary of Clinical Use Click here for help
Phase 2 clinical trials for thymic carcinoma (NCT01011439), malignant thymoma (NCT01301391) and unresectable/metastatic hepatocellular carcinoma (NCT03109886) are underway (Oct 2018). All of these studies are delivering the drug as milciclib maleate.